MNK, HZNP, ENDP Earnings all Looked GoodCould be a bottom in specialty pharama space. Everybody knew there was going to be pricing pressure but these names have all now reported stronger than expected Q2 numbers. The worst of worst Endo even affirmed revenue and EPS from Q1 guidance. Clearly there has been no further deterioration in pricing.